Obsessive-compulsive disorder (OCD) is a relatively common neuropsychiatric disorder affecting between 1.6 and 3.2% of the population. A number of studies have previously reported increased incidence of OCD, or exacerbation of preexisting symptoms in females during reproductive events. Since these periods are known to involve fluctuating levels of gonadal hormones, these steroids have been suggested to be involved in modulating the course of the disorder. However, to date, only a few studies have measured hormone levels and obsessive-compulsive (OC) symptoms concurrently; thus, direct evidence for this relationship is limited. In turn, investigations into neurotransmission in OC individuals have been more extensive, and have implicated the serotonergic, dopaminergic, and glutamatergic neurotransmitter systems in OCD pathology. There is evidence suggesting that reproductive hormones estrogens and progesterone can modulate neurotransmission in the aforementioned signaling pathways by regulating the expression of receptors and channels, as well as the synthesis and release of the neurotransmitter itself. Overall, estrogen and progesterone appear to enhance serotonin signaling, which has been associated with improved OC symptoms. The effect of the gonadal hormones in dopaminergic and glutamatergic signaling is much more variable, highlighting the need for further research in this field. The existing evidence shows that gonadal hormones can have profound impacts on neurotransmission in the brain, leading to the conclusion that the hormonal fluctuations during reproductive events are a plausible factor contributing to the change in OCD course during these times.

1.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). Arlington, American Psychiatric Publishing, 2013.
2.
Uguz F, Akman C, Kaya N, Cilli AS: Postpartum-onset obsessive-compulsive disorder: incidence, clinical features, and related factors. J Clin Psychiatry 2007;68:132-138.
3.
Mattina GF, Steiner M: The need for inclusion of sex and age of onset variables in genetic association studies of obsessive-compulsive disorder: overview. Prog Neuropsychopharmacol Biol Psychiatry 2016;67:107-116.
4.
Forray A, Focseneanu M, Pittman B, McDougle CJ, Epperson CN: Onset and exacerbation of obsessive-compulsive disorder in pregnancy and the postpartum period. J Clin Psychiatry 2010;71:1061-1068.
5.
Guglielmi V, Vulink NCC, Denys D, Wang Y, Samuels JF, Nestadt G: Obsessive-compulsive disorder and female reproductive cycle events: results from the OCD and reproduction collaborative study. Depress Anxiety 2014;31:979-987.
6.
Uguz F, Kaya V, Gezginc K, Kayhan F, Cicek E: Clinical correlates of worsening in obsessive-compulsive symptoms during pregnancy. Gen Hosp Psychiatry 2011;33:197-199.
7.
Russell EJ, Fawcett JM, Mazmanian D: Risk of obsessive-compulsive disorder in pregnant and postpartum women: a meta-analysis. J Clin Psychiatry 2013;74:377-385.
8.
Avgoustinaki PD, Mitsopoulou E, Chlouverakis G, Triantafillou T, Venihaki M, Koukouli S, et al: Sex steroids and personality traits in the middle luteal phase of healthy normally menstruating young professional women. Hormones (Athens) 2012;11:333-343.
9.
Fernández-Guasti A, Agrati D, Reyes R, Ferreira A: Ovarian steroids counteract serotonergic drugs actions in an animal model of obsessive-compulsive disorder. Psychoneuroendocrinology 2006;31:924-934.
10.
Yadin E, Friedman E, Bridger WH: Spontaneous alternation behavior: an animal model for obsessive-compulsive disorder? Pharmacol Biochem Behav 1991;40:311-315.
11.
Flaisher-Grinberg S, Albelda N, Gitter L, Weltman K, Arad M, Joel D: Ovarian hormones modulate “compulsive” lever-pressing in female rats. Horm Behav 2009;55:356-365.
12.
Stein DJ: Obsessive-compulsive disorder. Lancet 2002;360:397-405.
13.
Pittenger C, Bloch MH, Williams K: Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther 2011;132:314-332.
14.
Broocks A, Pigott TA, Hill JL, Canter S, Grady TA, L'heureux F, et al: Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder OCD : behavioral and biological results. Psychiatry Res 1998;79:11-20.
15.
Fineberg NA, Reghunandanan S, Brown A, Pampaloni I: Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond. Aust N Z J Psychiatry 2013;47:121-141.
16.
Insel TR, Mueller EA, Alterman I, Linnoila M, Murphy DL: Obsessive-compulsive disorder and serotonin: is there a connection? Biol Psychiatry 1985;20:1174-1188.
17.
Stengler-Wenzke K, Müller U, Angermeyer MC, Sabri O, Hesse S: Reduced serotonin transporter-availability in obsessive-compulsive disorder (OCD). Eur Arch Psychiatry Clin Neurosci 2004;254:252-255.
18.
Hesse S, Müller U, Lincke T, Barthel H, Villmann T, Angermeyer MC, et al: Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry Res Neuroimaging 2005;140:63-72.
19.
Zitterl W, Aigner M, Stompe T, Zitterl-Eglseer K, Gutierrez-Lobos K, Schmidl-Mohl B, et al: [123I]-beta-CIT SPECT imaging shows reduced thalamus-hypothalamus serotonin transporter availability in 24 drug-free obsessive-compulsive checkers. Neuropsychopharmacology 2007;32:1661-1668.
20.
Zitterl W, Aigner M, Stompe T, Zitterl-Eglseer K, Gutierrez-Lobos K, Wenzel T, et al: Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder. Neuropsychopharmacology 2008;33:3126-3134.
21.
Pogarell O, Hamann C, Pöpperl G, Juckel G, Choukèr M, Zaudig M, et al: Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. Biol Psychiatry 2003;54:1406-1413.
22.
Simpson HB, Lombardo I, Slifstein M, Huang HY, Hwang D-R, Abi-Dargham A, et al: Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [11C]McN 5652. Biol Psychiatry 2003;54:1414-1421.
23.
Bethea CL, Reddy AP: Effect of ovarian steroids on gene expression related to synapse assembly in serotonin neurons of macaques. J Neurosci Res 2012;90:1324-1334.
24.
Lokuge S, Frey BN, Foster JA, Soares CN, Steiner M: Depression in women: windows of vulnerability and new insights into the link between estrogen and serotonin. J Clin Psychiatry 2011;72:e1563-e1569.
25.
Kunimura Y, Iwata K, Iijima N, Kobayashi M, Ozawa H: Effect of sex steroid hormones on the number of serotonergic neurons in rat dorsal raphe nucleus. Neurosci Lett 2015;594:127-132.
26.
Pecins-Thompson M, Brown NA, Kohama SG, Bethea CL: Ovarian steroid regulation of tryptophan hydroxylase mRNA expression in rhesus macaques. J Neurosci 1996;16:7021-7029.
27.
Aggarwal M, Puri V, Puri S: Effects of estrogen on the serotonergic system and calcitonin gene-related peptide in trigeminal ganglia of rats. Ann Neurosci 2012;19:151-157.
28.
Sanchez RL, Reddy AP, Centeno ML, Henderson JA, Bethea CL: A second tryptophan hydroxylase isoform, TPH-2 mRNA, is increased by ovarian steroids in the raphe region of macaques. Mol Brain Res 2005;135:194-203.
29.
Bethea CL, Mirkes SJ, Shively CA, Adams MR: Steroid regulation of tryptophan hydroxylase protein in the dorsal raphe of macaques. Biol Psychiatry 2000;47:562-576.
30.
Smith LJ, Henderson JA, Abell CW, Bethea CL: Effects of ovarian steroids and raloxifene on proteins that synthesize, transport, and degrade serotonin in the raphe region of macaques. Neuropsychopharmacology 2004;29:2035-2045.
31.
Hildebrandt T, Alfano L, Tricamo M, Pfaff DW: Conceptualizing the role of estrogens and serotonin in the development and maintenance of bulimia nervosa. Clin Psychol Rev 2010;30:655-668.
32.
Luine VN, McEwen BS: Effect of oestradiol on turnover of type A monoamine oxidase in brain. J Neurochem 1977;28:1221-1227.
33.
Ortega-Corona BG, Valencia-Sánchez A, Kubli-Garfias C, Anton-Tay F, Salazar LA, Villarreal JE, et al: Hypothalamic monoamine oxidase activity in ovariectomized rats after sexual behavior restoration. Arch Med Res 1994;25:337-340.
34.
Holschneider DP, Kumazawa T, Chen K, Shih JC: Tissue-specific effects of estrogen on monoamine oxidase A and B in the rat. Life Sci 1998;63:155-160.
35.
Vulink NCC, Denys D, Bus L, Westenberg HGM: Female hormones affect symptom severity in obsessive-compulsive disorder. Int Clin Psychopharmacol 2006;21:171-175.
36.
Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø: Association of hormonal contraception with depression. JAMA Psychiatry 2016;382:1575-1586.
37.
Sacher J, Wilson AA, Houle S, Rusjan P, Hassan S, Bloomfield PM, et al: Elevated brain monoamine oxidase A binding in the early postpartum period. Arch Gen Psychiatry 2010;67:468-474.
38.
Rekkas PV, Wilson AA, Lee VWH, Yogalingam P, Sacher J, Rusjan P, et al: Greater monoamine oxidase a binding in perimenopausal age as measured with carbon 11-labeled harmine positron emission tomography. JAMA Psychiatry 2014;71:873-879.
39.
Sumner BE, Grant KE, Rosie R, Hegele- Hartung C, Fritzemeier K-H, Fink G: Effects of tamoxifen on serotonin transporter and 5-hydroxytryptamine(2A) receptor binding sites and mRNA levels in the brain of ovariectomized rats with or without acute estradiol replacement. Mol Brain Res 1999;73:119-128.
40.
McQueen JK, Wilson H, Fink G: Estradiol-17β increase serotonin transporter (SERT) mRNA levels and the density of SERT-binding sites in female rat brain. Mol Brain Res 1997;45:13-23.
41.
Pecins-Thompson M, Brown NA, Bethea CL: Regulation of serotonin re-uptake transporter mRNA expression by ovarian steroids in rhesus macaques. Brain Res Mol Brain Res 1998;53:120-129.
42.
Charoenphandhu J, Teerapornpuntakit J, Nuntapornsak A, Krishnamra N, Charoenphandhu N: Anxiety-like behaviors and expression of SERT and TPH in the dorsal raphé of estrogen- and fluoxetine-treated ovariectomized rats. Pharmacol Biochem Behav 2011;98:503-510.
43.
Chavez C, Hollaus M, Scarr E, Pavey G, Gogos A, van den Buuse M: The effect of estrogen on dopamine and serotonin receptor and transporter levels in the brain: an autoradiography study. Brain Res 2010;1321:51-59.
44.
Frokjaer VG, Pinborg A, Holst KK, Overgaard A, Henningsson S, Heede M, et al: Role of serotonin transporter changes in depressive responses to sex-steroid hormone manipulation: a positron emission tomography study. Biol Psychiatry 2015;78:534-543.
45.
Kranz GS, Wadsak W, Kaufmann U, Savli M, Baldinger P, Gryglewski G, et al: High-dose testosterone treatment increases serotonin transporter binding in transgender people. Biol Psychiatry 2015;78:525-533.
46.
Jovanovic H, Kocoska-Maras L, Rådestad AF, Halldin C, Borg J, Hirschberg AL, et al: Effects of estrogen and testosterone treatment on serotonin transporter binding in the brain of surgically postmenopausal women - a PET study. Neuroimage 2015;106:47-54.
47.
Akimova E, Lanzenberger R, Kasper S: The serotonin-1A receptor in anxiety disorders. Biol Psychiatry 2009;66:627-635.
48.
Österlund MK, Hurd YL: Acute 17β-estradiol treatment down-regulates serotonin 5HT1A receptor mRNA expression in the limbic system of female rats. Mol Brain Res 1998;55:169-172.
49.
Sánchez MG, Estrada-Camarena E, Bélanger N, Morissette M, Di Paolo T: Estradiol modulation of cortical, striatal and raphe nucleus 5-HT1A and 5-HT2A receptors of female hemiparkinsonian monkeys after long-term ovariectomy. Neuropharmacology 2011;60:642-652.
50.
Creech RD, Li Q, Carrasco GA, Van de Kar LD, Muma NA: Estradiol induces partial desensitization of serotonin 1A receptor signaling in the paraventricular nucleus of the hypothalamus and alters expression and interaction of RGSZ1 and Gαz. Neuropharmacology 2012;62:2040-2049.
51.
Hiroi R, Neumaier JF: Estrogen decreases 5-HT1B autoreceptor mRNA in selective subregion of rat dorsal raphe nucleus: inverse association between gene expression and anxiety behavior in the open field. Neuroscience 2009;158:456-464.
52.
Kranz GS, Rami-Mark C, Kaufmann U, Baldinger P, Hahn A, Höflich A, et al: Effects of hormone replacement therapy on cerebral serotonin-1A receptor binding in postmenopausal women examined with [carbonyl-11C]WAY-100635. Psychoneuroendocrinology 2014;45:1-10.
53.
Zhang G, Stackman RW: The role of serotonin 5-HT2A receptors in memory and cognition. Front Pharmacol 2015;6:225.
54.
Sumner BE, Fink G: Estrogen increases the density of 5-hydroxytryptamine(2A) receptors in cerebral cortex and nucleus accumbens in the female rat. J Steroid Biochem Mol Biol 1995;54:15-20.
55.
Moses EL, Drevets WC, Smith G, Mathis CA, Kalro BN, Butters MA, et al: Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study. Biol Psychiatry 2000;48:854-860.
56.
Kugaya A, Epperson CN, Zoghbi S, van Dyck CH, Hou Y, Fujita M, et al: Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry 2003;160:1522-1524.
57.
Compton J, Travis MJ, Norbury R, Erlandsson K, van Amelsvoort T, Daly E, et al: Long-term estrogen therapy and 5-HT2A receptor binding in postmenopausal women; a single photon emission tomography (SPET) study. Horm Behav 2008;53:61-68.
58.
Lu NZ, Shlaes TA, Gundlah C, Dziennis SE, Lyle RE, Bethea CL: Ovarian steroid action on tryptophan hydroxylase protein and serotonin compared to localization of ovarian steroid receptors in midbrain of guinea pigs. Endocrine 1999;11:257-267.
59.
Gereau RW, Kedzie KA, Renner KJ: Effect of progesterone on serotonin turnover in rats primed with estrogen implants into the ventromedial hypothalamus. Brain Res Bull 1993;32:293-300.
60.
Bethea CL, Gundlah C, Mirkes SJ: Ovarian steroid action in the serotonin neural system of macaques. Novartis Found Symp 2000;230:112-130; discussion 130-133.
61.
Bethea CL, Lu NZ, Gundlah C, Streicher JM: Diverse actions of ovarian steroids in the serotonin neural system. Front Neuroendocrinol 2002;23:41-100.
62.
Gundlah C, Lu NZ, Bethea CL: Ovarian steroid regulation of monoamine oxidase-A and -B mRNAs in the macaque dorsal raphe and hypothalamic nuclei. Psychopharmacology (Berl) 2002;160:271-282.
63.
Stein P, Baldinger P, Kaufmann U, Christina R-M, Hahn A, Höflich A, et al: Relation of progesterone and DHEAS serum levels to 5-HT1A receptor binding potential in pre- and postmenopausal women. Psychoneuroendocrinology 2014;46:52-63.
64.
Birzniece V, Johansson I-M, Wang M-D, Bäckström T, Olsson T: Ovarian hormone effects on 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptor mRNA expression in the ventral hippocampus and frontal cortex of female rats. Neurosci Lett 2002;319:157-161.
65.
Koo M-S, Kim E-J, Roh D, Kim C-H: Role of dopamine in the pathophysiology and treatment of obsessive-compulsive disorder. Expert Rev Neurother 2010;10:275-290.
66.
Stein DJ: Neurobiology of the obsessive-compulsive spectrum disorders. Biol Psychiatry 2000;47:296-304.
67.
Vulink NCC, Denys D, Westenberg HGM: Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study. J Clin Psychiatry 2005;66:228-230.
68.
Szechtman H, Sulis W, Eilam D: Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD). Behav Neurosci 1998;112:1475-1485.
69.
Eagle DM, Noschang C, d'Angelo L-SC, Noble CA, Day JO, Dongelmans ML, et al: The dopamine D2/D3 receptor agonist quinpirole increases checking-like behaviour in an operant observing response task with uncertain reinforcement: a novel possible model of OCD. Behav Brain Res 2014;264:207-229.
70.
Moresco RM, Pietra L, Henin M, Panzacchi A, Locatelli M, Bonaldi L, et al: Fluvoxamine treatment and D2 receptors: a pet study on OCD drug-naïve patients. Neuropsychopharmacology 2007;32:197-205.
71.
Kapur S, Remington G: Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153:466-476.
72.
Denys D, Zohar J, Westenberg HGM: The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry 2004;6565:11-17.
73.
Metin O, Yazici K, Tot S, Yazici AE: Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum Psychopharmacol 2003;18:463-467.
74.
Olver JS, O'Keefe G, Jones GR, Burrows GD, Tochon-Danguy HJ, Ackermann U, et al: Dopamine D1 receptor binding in the striatum of patients with obsessive-compulsive disorder. J Affect Disord 2009;114:321-326.
75.
Olver JS, O'Keefe G, Jones GR, Burrows GD, Tochon-Danguy HJ, Ackermann U, et al: Dopamine D1 receptor binding in the anterior cingulate cortex of patients with obsessive-compulsive disorder. Psychiatry Res 2010;183:85-88.
76.
Pitman RK: A cybernetic model of obsessive-compulsive psychopathology. Compr Psychiatry 1987;28:334-343.
77.
Denys D, van der Wee N, Janssen J, De Geus F, Westenberg HG: Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder. Biol Psychiatry 2004;55:1041-1045.
78.
Perani D, Garibotto V, Gorini A, Moresco RM, Henin M, Panzacchi A, et al: In vivo PET study of 5HT2A serotonin and D2 dopamine dysfunction in drug-naive obsessive-compulsive disorder. Neuroimage 2008;42:306-314.
79.
van der Wee NJ, Stevens H, Hardeman JA, Mandl RC, Denys DA, van Megen HJ, et al: Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]{beta}-CIT SPECT. Am J Psychiatry 2004;161:2201-2206.
80.
Pogarell O, Poepperl G, Mulert C, Hamann C, Sadowsky N, Riedel M, et al: SERT and DAT availabilities under citalopram treatment in obsessive-compulsive disorder (OCD). Eur Neuropsychopharmacol 2005;15:521-524.
81.
Di Paolo T: Modulation of brain dopamine transmission by sex steroids. Rev Neurosci 1994;5:27-41.
82.
McDermott JL, Liu B, Dluzent DE: Sex differences and effects of estrogen on dopamine and DOPAC release from the striatum of male and female CD-1 mice. Exp Neurol 1994;125:306-311.
83.
Zsarnovszky A, Scalise TJ, Horvath TL, Naftolin F: Estrogen effects on tyrosine hydroxylase-immunoreactive cells in the ventral mesencephalon of the female rat: further evidence for the two cell hypothesis of dopamine function. Brain Res 2000;868:363-366.
84.
Kritzer M, Adler A, Bethea C: Ovarian hormone influences on the density of immunoreactivity for tyrosine hydroxylase and serotonin in the primate corpus striatum. Neuroscience 2003;122:757-772.
85.
Becker JB: Gender differences in dopaminergic function in striatum and nucleus accumbens. Pharmacol Biochem Behav 1999;64:803-812.
86.
Becker JB: Direct effect of 17 beta-estradiol on striatum: sex differences in dopamine release. Synapse 1990;5:157-164.
87.
Thompson TL, Moss RL: Estrogen regulation of dopamine release in the nucleus accumbens: genomic- and nongenomic-mediated effects. J Neurochem 1994;62:1750-1756.
88.
Bossé R, Rivest R, Di Paolo T: Ovariectomy and estradiol treatment affect the dopamine transporter and its gene expression in the rat brain. Brain Res Mol Brain Res 1997;46:343-346.
89.
Sánchez MG, Morissette M, Di Paolo T: Effect of a chronic treatment with 17β-estradiol on striatal dopamine neurotransmission and the Akt/GSK3 signaling pathway in the brain of ovariectomized monkeys. Psychoneuroendocrinology 2012;37:280-291.
90.
Gardiner SA, Morrison MF, Mozley PD, Mozley LH, Brensinger C, Bilker W, et al: Pilot study on the effect of estrogen replacement therapy on brain dopamine transporter availability in healthy, postmenopausal women. Am J Geriatr Psychiatry 2004;12:621-630.
91.
Zhou W, Cunningham KA, Thomas ML: Estrogen regulation of gene expression in the brain: a possible mechanism altering the response to psychostimulants in female rats. Mol Brain Res 2002;100:75-83.
92.
Attali G, Weizman A, Gil-Ad I, Rehavi M: Opposite modulatory effects of ovarian hormones on rat brain dopamine and serotonin transporters. Brain Res 1997;756:153-159.
93.
Lévesque D, Di Paolo T: Effect of the rat estrous cycle at ovariectomy on striatal D-1 dopamine receptors. Brain Res Bull 1990;24:281-284.
94.
Bossé R, DiPaolo T: The modulation of brain dopamine and GABAA receptors by estradiol: a clue for CNS changes occurring at menopause. Cell Mol Neurobiol 1996;16:199-212.
95.
Lévesque D, Di Paolo T: Chronic estradiol treatment increases ovariectomized rat striatal D-1 dopamine receptors. Life Sci 1989;45:1813-1820.
96.
Lévesque D, Di Paolo T: Dopamine receptor reappearance after irreversible receptor blockade: effect of chronic estradiol treatment of ovariectomized rats. Mol Pharmacol 1991;39:659-665.
97.
Lévesque D, Gagnon S, Di Paolo T: Striatal D1 dopamine receptor density fluctuates during the rat estrous cycle. Neurosci Lett 1989;98:345-350.
98.
Lévesque D, Di Paolo T: Rapid conversion of high into low striatal D2-dopamine receptor agonist binding states after an acute physiological dose of 17 beta-estradiol. Neurosci Lett 1988;88:113-118.
99.
Landry M, Lévesque D, Di Paolo T: Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain. Neuroendocrinology 2002;76:214-222.
100.
Nordström AL, Olsson H, Halldin C: A PET study of D2 dopamine receptor density at different phases of the menstrual cycle. Psychiatry Res 1998;83:1-6.
101.
Di Paolo T, Lévesque D, Daigle M: A physiological dose of progesterone affects rat striatum biogenic amine metabolism. Eur J Pharmacol 1986;125:11-16.
102.
Petitclerc M, Bédard PJ, Di Paolo T: Progesterone releases dopamine in male and female rat striatum: a behavioral and microdialysis study. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:491-497.
103.
Becker JB, Rudick CN: Rapid effects of estrogen or progesterone on the amphetamine-induced increase in striatal dopamine are enhanced by estrogen priming: a microdialysis study. Pharmacol Biochem Behav 1999;64:53-57.
104.
Morissette M, Di Paolo T: Effect of chronic estradiol and progesterone treatments of ovariectomized rats on brain dopamine uptake sites. J Neurochem 1993;60:1876-1883.
105.
Morissette M, Biron D, Di Paolo T: Effect of estradiol and progesterone on rat striatal dopamine uptake sites. Brain Res Bull 1990;25:419-422.
106.
Fernández-Ruiz JJ, Amor JC, Ramos JA: Time-dependent effects of estradiol and progesterone on the number of striatal dopaminergic D2-receptors. Brain Res 1989;476:388-395.
107.
Lévesque D, Di Paolo T: Modulation by estradiol and progesterone of the GTP effect on striatal D-2 dopamine receptors. Biochem Pharmacol 1993;45:723-733.
108.
Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S: Glutamatergic dysfunction in OCD. Neuropsychopharmacology 2005;30:1735-1740.
109.
Bhattacharyya S, Khanna S, Chakrabarty K, Mahadevan A, Christopher R, Shankar SK: Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder. Neuropsychopharmacology 2009;34:2489-2496.
110.
Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ: Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 2000;39:1096-1103.
111.
Rosenberg DR, Mirza Y, Russell A, Tang J, Smith JM, Banerjee SP, et al: Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry 2004;43:1146-1153.
112.
Ortiz AE, Ortiz AG, Falcon C, Morer A, Plana MT, Bargalló N, et al: 1H-MRS of the anterior cingulate cortex in childhood and adolescent obsessive-compulsive disorder: a case-control study. Eur Neuropsychopharmacol 2015;25:60-68.
113.
Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G: Riluzole in the treatment of mood and anxiety disorders. CNS Drugs 2008;22:761-786.
114.
Coric V, Milanovic S, Wasylink S, Patel P, Malison R, Krystal JH: Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl) 2003;167:219-220.
115.
Pittenger C, Bloch MH, Wasylink S, Billingslea E, Simpson R, Jakubovski E, et al: Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. J Clin Psychiatry 2015;76:1075-1084.
116.
Grant PJ, Joseph LA, Farmer CA, Luckenbaugh DA, Lougee LC, Zarate CA, et al: 12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder. Neuropsychopharmacology 2014;39:1453-1459.
117.
Pittenger C: Glutamate modulators in the treatment of obsessive-compulsive disorder. Psychiatr Ann 2015;45:308-315.
118.
Wu K, Hanna GL, Rosenberg DR, Arnold PD: The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol Biochem Behav 2012;100:726-735.
119.
Pauls DL, Abramovitch A, Rauch SL, Geller DA: Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective. Nat Rev Neurosci 2014;15:410-424.
120.
Kalra SK, Swedo SE: Children with obsessive-compulsive disorder: are they just “little adults?” J Clin Invest 2009;119:737-746.
121.
Teyler TJ, Vardaris RM, Lewis D, Rawitch AB: Gonadal steroids: effects on excitability of hippocampal pyramidal cells. Science 1980;209:1017-1018.
122.
Sharrow KM, Kumar A, Foster TC: Calcineurin as a potential contributor in estradiol regulation of hippocampal synaptic function. Neuroscience 2002;113:89-97.
123.
Schwarz JM, Liang S-L, Thompson SM, McCarthy MM: Estradiol induces hypothalamic dendritic spines by enhancing glutamate release: a mechanism for organizational sex differences. Neuron 2008;58:584-598.
124.
Kuo J, Hariri OR, Bondar G, Ogi J, Micevych P: Membrane estrogen receptor-alpha interacts with metabotropic glutamate receptor type 1a to mobilize intracellular calcium in hypothalamic astrocytes. Endocrinology 2009;150:1369-1376.
125.
Lan Y-L, Zhao J, Li S: Estrogen receptors' neuroprotective effect against glutamate-induced neurotoxicity. Neurol Sci 2014;35:1657-1662.
126.
Gazzaley AH, Weiland NG, McEwen BS, Morrison JH: Differential regulation of NMDAR1 mRNA and protein by estradiol in the rat hippocampus. J Neurosci 1996;16:6830-6838.
127.
Cyr M, Ghribi O, Di Paolo T: Regional and selective effects of oestradiol and progesterone on NMDA and AMPA receptors in the rat brain. J Neuroendocrinol 2000;12:445-452.
128.
Le Saux M, Di Paolo T: Influence of oestrogenic compounds on monoamine transporters in rat striatum. J Neuroendocrinol 2006;18:25-32.
129.
Tian Z, Wang Y, Zhang N, Guo Y, Feng B, Liu S, et al: Estrogen receptor GPR30 exerts anxiolytic effects by maintaining the balance between GABAergic and glutamatergic transmission in the basolateral amygdala of ovariectomized mice after stress. Psychoneuroendocrinology 2013;38:2218-2233.
130.
Nebieridze N, Zhang X, Chachua T, Velíšek L, Stanton PK, Velíšková J: β-Estradiol unmasks metabotropic receptor-mediated metaplasticity of NMDA receptor transmission in the female rat dentate gyrus. Psychoneuroendocrinology 2012;37:1845-1854.
131.
Keller JN, Germeyer A, Begley JG, Mattson MP: 17Beta-estradiol attenuates oxidative impairment of synaptic Na+/K+-ATPase activity, glucose transport, and glutamate transport induced by amyloid beta-peptide and iron. J Neurosci Res 1997;50:522-530.
132.
Liang Z, Valla J, Sefidvash-Hockley S, Rogers J, Li R: Effects of estrogen treatment on glutamate uptake in cultured human astrocytes derived from cortex of Alzheimer's disease patients. J Neurochem 2002;80:807-814.
133.
Sato K, Matsuki N, Ohno Y, Nakazawa K: Estrogens inhibit l-glutamate uptake activity of astrocytes via membrane estrogen receptor alpha. J Neurochem 2003;86:1498-1505.
134.
Cimarosti H, O'Shea RD, Jones NM, Horn AP, Simão F, Zamin LL, et al: The effects of estradiol on estrogen receptor and glutamate transporter expression in organotypic hippocampal cultures exposed to oxygen-glucose deprivation. Neurochem Res 2006;31:483-490.
135.
Jelks KB, Wylie R, Floyd CL, McAllister AK, Wise P: Estradiol targets synaptic proteins to induce glutamatergic synapse formation in cultured hippocampal neurons: critical role of estrogen receptor-alpha. J Neurosci 2007;27:6903-6913.
136.
Waters EM, Mitterling K, Spencer JL, Mazid S, McEwen BS, Milner TA: Estrogen receptor alpha and beta specific agonists regulate expression of synaptic proteins in rat hippocampus. Brain Res 2009;1290:1-11.
137.
Ma X-M, Huang J-P, Kim E-J, Zhu Q, Kuchel GA, Mains RE, et al: Kalirin-7, an important component of excitatory synapses, is regulated by estradiol in hippocampal neurons. Hippocampus 2011;21:661-677.
138.
Feng X-Q, Dong Y, Fu Y-M, Zhu Y-H, Sun J-L, Wang Z, et al: Progesterone inhibition of dopamine-induced increase in frequency of spontaneous excitatory postsynaptic currents in rat prelimbic cortical neurons. Neuropharmacology 2004;46:211-222.
139.
Bethea CL, Reddy AP: Ovarian steroids increase glutamatergic related gene expression in serotonin neurons of macaques. Mol Cell Neurosci 2012;49:251-262.
140.
El-Bakri NK, Islam A, Zhu S, Elhassan A, Mohammed A, Winblad B, et al: Effects of estrogen and progesterone treatment on rat hippocampal NMDA receptors: relationship to Morris water maze performance. J Cell Mol Med 2004;8:537-544.
141.
Son I, Shin H-J, Ryu J-H, Kim H-K, Do S-H, Zuo Z: Progesterone increases the activity of glutamate transporter type 3 expressed in Xenopus oocytes. Eur J Pharmacol 2013;715:414-419.
142.
Mitrovic AD, Maddison JE, Johnston GAR: Influence of the oestrous cycle on L-glutamate and L-aspartate transport in rat brain synaptosomes. Neurochem Int 1999;34:101-108.
143.
Leckman JF, Goodman WK, North WG, Chappell PB, Price LH, Pauls DL, et al: Elevated cerebrospinal fluid levels of oxytocin in obsessive-compulsive disorder. Comparison with Tourette's syndrome and healthy controls. Arch Gen Psychiatry 1994;51:782-792.
144.
Marazziti D, Baroni S, Giannaccini G, Catena-Dell'Osso M, Piccinni A, Massimetti G, et al: Plasma oxytocin levels in untreated adult obsessive-compulsive disorder patients. Neuropsychobiology 2015;72:74-80.
145.
Leckman JF, Goodman WK, North WG, Chappell PB, Price LH, Pauls DL, et al: The role of central oxytocin in obsessive compulsive disorder and related normal behavior. Psychoneuroendocrinology 1994;19:723-749.
146.
Humble MB, Uvnäs-Moberg K, Engström I, Bejerot S: Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study. BMC Psychiatry 2013;13:344.
147.
Altemus M, Jacobson KR, Debellis M, Kling M, Pigott T, Murphy DL, et al: Normal CSF oxytocin and NPY levels in OCD. Biol Psychiatry 1999;45:931-933.
148.
den Boer JA, Westenberg HG: Oxytocin in obsessive compulsive disorder. Peptides 1992;13:1083-1085.
149.
Yoshida M, Takayanagi Y, Inoue K, Kimura T, Young LJ, Onaka T, et al: Evidence that oxytocin exerts anxiolytic effects via oxytocin receptor expressed in serotonergic neurons in mice. J Neurosci 2009;29:2259-2271.
150.
Kaya V, Uguz F, Sahingoz M, Gezginc K: Pregnancy-onset obsessive-compulsive disorder: clinical features, comorbidity, and associated factors. Klin Psikofarmakol Bul 2015;25:248-258.
151.
Labad J, Menchón JM, Alonso P, Segalàs C, Jiménez S, Vallejo J: Female reproductive cycle and obsessive-compulsive disorder. J Clin Psychiatry 2005;66:428-435.
152.
Kerlan V, Nahoul K, Le Martelot MT, Bervocivi JP: Longitudinal study of maternal plasma bioavailable testosterone and androstanediol glucuronide levels during pregnancy. Clin Endocrinol (Oxf) 1994;40:263-267.
153.
Meulenberg PM, Hofman JA: Maternal testosterone and fetal sex. J Steroid Biochem Mol Biol 1991;39:51-54.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.